Literature DB >> 23686701

Synergistic relationship between dipeptidyl peptidase IV and neutral endopeptidase expression and the combined prognostic significance in osteosarcoma patients.

Hongtao Zhang1, Haibin Lin, Xiaoqiong Mo, Guoli Chen, Lijun Lin.   

Abstract

Neutral endopeptidase (NEP/CD10) and dipeptidyl peptidase IV (DPP IV/CD26) are both ubiquitous glycopeptidases which play important roles in tumor pathogenesis and development. The aim of this study was to investigate the expression patterns and the prognostic significance of CD10 and CD26 in osteosarcoma patients. CD10 and CD26 expression in 116 pairs of primary osteosarcoma and corresponding noncancerous bone tissue samples from the same specimens were detected by immunohistochemistry. The Spearman's correlation was calculated between the expression levels of CD10 and CD26 in osteosarcoma tissues. The associations of CD10 and CD26 expression with the clinicopathologic features and with the prognosis of osteosarcoma were subsequently assessed. Both CD10 expression and CD26 expression in osteosarcoma tissues were significantly higher than those in corresponding noncancerous bone tissue samples (both P < 0.001). Overexpression of CD10 and CD26 were respectively observed in 68.10 % (79/116) and 70.69 % (82/116) of osteosarcoma tissues. A significant correlation was found between CD10 expression and CD26 expression in osteosarcoma tissues (r = 0.83, P < 0.001). In addition, combined overexpression of CD10 and CD26 was observed in 52.59 % (61/116) of osteosarcoma tissues. CD10-high/CD26-high expression was significantly correlated with advanced clinical stage (P = 0.001), positive metastatic status (P = 0.001), shorter overall (P < 0.001) and disease-free (P < 0.001) survival in patients with osteosarcomas. Furthermore, multivariate survival analysis showed that clinical stage, metastatic status, CD10 expression, CD26 expression and combined expression of CD10/CD26 were all independent prognostic factors for predicting both overall and disease-free survival of osteosarcoma patients. Interestingly, combined expression of CD10/CD26 had a better prognostic value than other features. This retrospective study offer the convincing evidence for the first time that the overexpression of CD10 or CD26 may be an important feature of human osteosarcomas, and the combined expression of CD10/CD26 may be an efficient prognostic indicator for this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23686701     DOI: 10.1007/s12032-013-0608-6

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  33 in total

1.  Solid-pseudopapillary tumor of the pancreas: immunohistochemical localization of neuroendocrine markers and CD10.

Authors:  K Notohara; S Hamazaki; C Tsukayama; S Nakamoto; K Kawabata; K Mizobuchi; K Sakamoto; S Okada
Journal:  Am J Surg Pathol       Date:  2000-10       Impact factor: 6.394

Review 2.  Molecular classification of osteosarcoma.

Authors:  Ching C Lau
Journal:  Cancer Treat Res       Date:  2009

3.  Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade.

Authors:  Nikita A Makretsov; Malcolm Hayes; Beverley A Carter; Shahriar Dabiri; C Blake Gilks; David G Huntsman
Journal:  Mod Pathol       Date:  2006-11-24       Impact factor: 7.842

Review 4.  Dipeptidyl peptidase in autoimmune pathophysiology.

Authors:  Kei Ohnuma; Osamu Hosono; Nam H Dang; Chikao Morimoto
Journal:  Adv Clin Chem       Date:  2011       Impact factor: 5.394

5.  Potential of soluble CD26 as a serum marker for colorectal cancer detection.

Authors:  Oscar J Cordero; Monica Imbernon; Loretta De Chiara; Vicenta S Martinez-Zorzano; Daniel Ayude; Maria Paez de la Cadena; F Javier Rodriguez-Berrocal
Journal:  World J Clin Oncol       Date:  2011-06-10

6.  Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.

Authors:  A Horiguchi; D Y T Chen; O B Goodman; R Zheng; R Shen; H Guan; L B Hersh; D M Nanus
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-06-12       Impact factor: 5.554

7.  Neutral endopeptidase: variable expression in human lung, inactivation in lung cancer, and modulation of peptide-induced calcium flux.

Authors:  A J Cohen; P A Bunn; W Franklin; C Magill-Solc; C Hartmann; B Helfrich; L Gilman; J Folkvord; K Helm; Y E Miller
Journal:  Cancer Res       Date:  1996-02-15       Impact factor: 12.701

Review 8.  On the origin of serum CD26 and its altered concentration in cancer patients.

Authors:  Oscar J Cordero; Francisco J Salgado; Montserrat Nogueira
Journal:  Cancer Immunol Immunother       Date:  2009-06-26       Impact factor: 6.968

9.  CD10 expression helps to differentiate basal cell carcinoma from trichoepithelioma.

Authors:  Mitra Heidarpour; Parvin Rajabi; Farzaneh Sajadi
Journal:  J Res Med Sci       Date:  2011-07       Impact factor: 1.852

View more
  5 in total

1.  New Borane-Protected Derivatives of α-Aminophosphonous Acid as Anti-Osteosarcoma Agents: ADME Analysis and Molecular Modeling, In Vitro Studies on Anti-Cancer Activities, and NEP Inhibition as a Possible Mechanism of Anti-Proliferative Activity.

Authors:  Magdalena Mizerska-Kowalska; Sylwia Sowa; Beata Donarska; Wojciech Płaziński; Adrianna Sławińska-Brych; Aleksandra Tomasik; Anna Ziarkowska; Krzysztof Z Łączkowski; Barbara Zdzisińska
Journal:  Int J Mol Sci       Date:  2022-06-16       Impact factor: 6.208

2.  Sox9 regulates hyperexpression of Wnt1 and Fzd1 in human osteosarcoma tissues and cells.

Authors:  Huancai Liu; Yanchun Chen; Fenghua Zhou; Linlin Jie; Leidong Pu; Jie Ju; Fengjie Li; Zhigang Dai; Xin Wang; Shuanhu Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

3.  Extracellular Nanovesicles Secreted by Human Osteosarcoma Cells Promote Angiogenesis.

Authors:  Francesca Perut; Laura Roncuzzi; Nicoletta Zini; Annamaria Massa; Nicola Baldini
Journal:  Cancers (Basel)       Date:  2019-06-05       Impact factor: 6.639

4.  CD26 as a Promising Biomarker for Predicting Prognosis in Patients with Pancreatic Tumors.

Authors:  Liang Yan; Xiuyun Tian; Chunxiang Ye; Xiaoya Guan; Bin Dong; Min Zhao; Jianhui Wu; Chunyi Hao
Journal:  Onco Targets Ther       Date:  2020-12-08       Impact factor: 4.147

Review 5.  CD26/DPP4 as a Therapeutic Target in Nonalcoholic Steatohepatitis Associated Hepatocellular Carcinoma.

Authors:  Sohji Nishina; Keisuke Hino
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.